This run could be short-lived.

Intellia Therapeutics Inc. NTLA shares are up on Monday following the FDA’s decision to lift the clinical hold on its ...

Intellia TherapeuticsNTLA stock shot higher Tuesday after the Food and Drug Administration said it would allow the company to restart a study of its gene-editing drug in patients with polyneuropathy.

Is On Investors’ Radar Intellia Therapeutics (NTLA) has drawn attention after a recent stretch of positive returns, with the stock up over the month, the past 3 months, and over the past year. For ...

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +15.82% and +94.22%, respectively, for the quarter ...

Intellia said the FDA removed the clinical hold on application for the Phase 3 clinical trial of nexiguran ziclumeran. The study is a randomized, double-blind, placebo-controlled trial evaluating the ...

The last time I wrote about Intellia Therapeutics (NTLA) it was with respect to a Seeking Alpha article entitled "Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity".

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine ...

Intellia is now able to continue both Phase III trials of nex-z. Credit: Piotr Swat / Shutterstock.com (Piotr Swat / Shutterstock.com) The US Food and Drug Administration (FDA) has released the ...

Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed the ...